KPIs & Operating Metrics(New)
Balance Sheet
Accumulated DepreciationAccumulated ExpensesAssetsBuildingsCash & EquivalentsCommon EquityDividends payablesGoodwillGoodwill & IntangiblesIntangiblesLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReal Estate - GrossReal Estate - NetReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Global Medical REIT (GMRE) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Global Medical REIT (GMRE) over the last 14 years, with Q3 2025 value amounting to $7.1 million.

  • Global Medical REIT's Cash & Equivalents rose 2446.27% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 million, marking a year-over-year increase of 2446.27%. This contributed to the annual value of $6.8 million for FY2024, which is 43325.51% up from last year.
  • Global Medical REIT's Cash & Equivalents amounted to $7.1 million in Q3 2025, which was up 2446.27% from $6.6 million recorded in Q2 2025.
  • Global Medical REIT's Cash & Equivalents' 5-year high stood at $7.2 million during Q4 2021, with a 5-year trough of $1.3 million in Q4 2023.
  • For the 5-year period, Global Medical REIT's Cash & Equivalents averaged around $4.6 million, with its median value being $5.3 million (2021).
  • Over the last 5 years, Global Medical REIT's Cash & Equivalents had its largest YoY gain of 43325.51% in 2024, and its largest YoY loss of 7104.06% in 2024.
  • Global Medical REIT's Cash & Equivalents (Quarter) stood at $7.2 million in 2021, then tumbled by 44.32% to $4.0 million in 2022, then crashed by 68.18% to $1.3 million in 2023, then skyrocketed by 433.26% to $6.8 million in 2024, then increased by 4.52% to $7.1 million in 2025.
  • Its Cash & Equivalents stands at $7.1 million for Q3 2025, versus $6.6 million for Q2 2025 and $5.4 million for Q1 2025.